Neurol. pro Praxi, 2002; 4: 193-198

Léčba tikových poruch v dětské psychiatrii

prof. MUDr. Ivana Drtílková CSc
Psychiatrická klinika LF MU a FN Brno

Keywords: Tourettův syndrom, tiky, farmakoterapie, léky prvé volby.

Published: December 31, 2002  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Drtílková I. Léčba tikových poruch v dětské psychiatrii. Neurol. praxi. 2002;3(4):193-198.

Přesná etiologie Tourettovy poruchy (TP) není jasná, má však pravděpodobně genetický podklad a neurochemickou komponentu. Starší a dosud často předepisovaný haloperidol by vzhledem k výrazným nežádoucí účinkům neměl být považován za preparát první volby. Mezi naše preparáty první volby patří tiaprid, risperidon, klonidin a klonazepam. Pokud tyto preparáty nemají dostatečný efekt, měli bychom doporučit olanzapin, pimozid nebo haloperidol. Nadějný se jeví rovněž potenciální efekt dalších preparátů, jako jsou ziprasidon nebo tetrabenazin. Pokud se spolu s TP vyskytuje obsedantně kompulzivní porucha (OCD), měla by být léčena kombinací selektivních inhibitorů zpětného vychytávání serotoninu (SSRI) s antagonisty dopaminových receptorů. Klonidin je racionální volba, pokud se vyskytuje společně Tourettova a hyperkinetická porucha.

Download citation

References

  1. Bagheri M. Recognition and management of Tourettes syndrome and tic disorder. American Family Physician 1999; 15: 1-16.
  2. Bruggeman R, van der Linden C. Risperidone versus pimozide in Tourette disorder: a comparative double-blind parallel group study. J. Clin. Psychiatry 2001; 62 (1): 50-56. Go to original source... Go to PubMed...
  3. Drtílková I, Balaštíková B. Tiaprid, clonazepam a clonidin u dětí s tikovou akomorbidní hyperkinetickou poruchou. ČS Psychiatrie 1997; suppl 3: 54-78.
  4. Gaffney G, Perry P, Lund B. Risperidone versus clonidine in the treatment of children and adolescents with Tourettes syndrome. J Am Acad Child Adol Psychiatry 2002; 41(3): 330-336. Go to original source... Go to PubMed...
  5. Goetz CG. Clonidine and clonazepam in Tourette syndrome 1992; Adv Neurol 58: 245-251.
  6. Horn S. Gilles de la Tourette syndrome. Clin Neuropharmacology 2001; 24: 125-128. Go to original source... Go to PubMed...
  7. Kossoff EH, Singer HS. Tourette syndrome: clinical characteristics and current management strategies. Paediatr Drugs 2001; 3 (5): 355-363. Go to original source... Go to PubMed...
  8. Kumar R, Lang AE. Tourette syndrome, sec. tic disorders. Neurol Clin 1997; 15: 309-331. Go to original source... Go to PubMed...
  9. Lomboroso PJ, Scahill L. Risperidone treatment of children and adolescents with chronic tic disorders. J Am Acas Child Adol Psychiatry 1996; 35 (7): 839-840.
  10. Onofrj M, Paci C. Olanzapine in severe Gilles de la Tourette syndrome: a 52 week double-blind cross-over study vs. low-dose pimozide. J Neurol 2000; 247 (6): 443 Go to original source... Go to PubMed...
  11. Pliszka SR, Greenhill L, et al. The Texas childrens medication algorithm project: report of the Texas consensus conference panel on medication treatment of ADHD. J Am Acad Adolesc Psychiatry 2000; 39 (7): 908-919. Go to original source... Go to PubMed...
  12. Robertson MM, Stern JS. Gilles de la Tourette syndrome: symptomatic treatment based on evidence. Eur Child Adolesc Psychiatry 2000; 9: 160-175. Go to original source... Go to PubMed...
  13. Růžička E. Role basálních ganglií u Parkinsonovy nemoci a dalších extrapyramidových poruch. In: Psychiatrie v medicíně a medicína v psychiatrii. Galén 2002: 236-237.
  14. Salle FR, Kurlan MD. Ziprasidone treatment of children and adolescents with Tourettes syndrome: a pilot study. J Am Acad Child Adol Psychiatry 2000; 39 (3): 292-298. Go to original source... Go to PubMed...
  15. Scahill L, Riddle MA. Fluoxetine has no marked effect on tic symptoms in patients with Tourettes syndrome: a double-blind placebo-controlled study. J Child Adol Psychopharmacology 1997; 7 (2): 75-85. Go to original source... Go to PubMed...




Neurology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.